NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Mersana Therapeutics, Inc. (MRSN) Stock Analysis

Mersana Therapeutics, Inc. (MRSN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

MRSN

$29.08

$0.00 (0.00%)

Last trade January 6, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MRSN with… →

MRSN Key Statistics

As of Jan 6, 2026
Trading
Open
$29.08
Previous Close
$29.08
52-Week Range
5.21–30.39
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.43
Valuation
Market Cap
$145.36M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.38
EPS (ttm)Profit attributable to each share over the last twelve months.
−13.95
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
−211.22%
1-Year Return
−14.47%
Dividend and dates
Avg Volume
136.78K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MRSN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+0.52%
2025−19.08%
2024 (partial year)−17.82%

As of January 6, 2026.

MRSN Valuation vs Biotechnology Median

Median of 656 stocks
MetricMRSNBiotechnology medianvs median
P/S ratio4.3815.260.3x the median
Profit margin−211.22%0.00%211.2 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values Mersana Therapeutics, Inc. (MRSN) at $145.36M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 102 employees.

Over the past 52 weeks the price has ranged from $5.21 to $30.39. The most recent close on file for MRSN is $29.08, dated January 6, 2026. The close was unchanged from the previous session. The latest close sits 458.16% above that 52-week low.

Financial Health

Trailing twelve-month revenue on file is $33.18M. The reported profit margin is −211.22%. That is 211.2 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −13.95.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 4.38. On price-to-sales that is 0.3 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is 0.43. Annualized volatility over the trailing 1 year is 236.05%. Over the trailing twelve months the price has returned −14.47%.

Growth & Income

No dividend is on file for MRSN.

The record holds one complete calendar year, 2025, which returned −19.08%. 2026 is still running; the price is +0.52% year to date.

Peer Comparison

Mersana Therapeutics, Inc. (MRSN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Mersana Therapeutics, Inc. MRSN $145.36M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Mersana Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of January 6, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Mersana Therapeutics, Inc.

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. As of January 6, 2026, Mersana Therapeutics, Inc. operates as a subsidiary of Day One Biopharmaceuticals, Inc.

Visit website →